CTKB Earnings Prediction
The chart below shows how CTKB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CTKB sees a +8.28% change in stock price 10 days leading up to the earnings, and a +4.34% change 10 days following the report. On the earnings day itself, the stock moves by -1.48%. This data can give you a slight idea of what to expect for the next quarter's release.
CTKB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
57.48M
-1.30%
11.60%
Gross Margin
58.55%
3.17%
3.96%
Operating Margin
5.20%
2266.67%
-163.03%
Net Margin
16.78%
77.57%
816.94%
EPS
0.07
75.00%
600.00%
No Data Available
CTKB Earnings Analysis
Cytek Biosciences Inc Corporation (CTKB.O) Earnings Conference Call
Positive
Revenue Growth in 2024: Full year revenue in 2024 grew 4% over 2023, reaching $200.5 million, driven by strong growth in service revenue and double-digit growth in international markets outside of the U.S.
Unit Volume Growth Surge: Unit volume growth in 2024 with placements of Full Spectrum Profiling (FSP) and imaging instruments up by 8.5% over 2023, outpacing the flow cytometry market and competition.
Strong Profitability Growth: Adjusted EBITDA of $22.4 million delivered a gain of more than 77% above the $12.6 million of adjusted EBITDA from 2023, demonstrating strong profitability growth.
Shareholder Value Commitment: Positive cash flow achieved again in 2024, with $21.6 million used for share repurchases, reflecting commitment to returning value to shareholders.
Service Revenue Growth: Service revenue grew 8% in the fourth quarter, mainly due to the growth in the total installed base of instruments, indicating strong customer engagement.
APAC Market Demand Surge: Strong demand in APAC markets, with 21% growth driven by China, and significant growth in other international markets, particularly Canada and Latin America.
Industry Standard Technology: Cytek's FSP technology has matured into the industry standard, with nearly 2,000 customers worldwide and over 2,300 peer-reviewed publications validating its use.
Instrument Placement Growth: Instruments placements increased, with 13% year-over-year growth of the Aurora cell sorter and 12% year-over-year growth of the Northern Lights System, showcasing product strength.
Service Gross Margin Improvement: The acquisition of Luminex enhanced technical capabilities and service gross margin, which improved from 15% in 2022 to 57% in 2024, demonstrating operational efficiency.
User Base Expansion: Cytek Cloud expanded its user base by more than 160% in 2024, now with over 16,000 users, indicating strong adoption of digital tools in research.
Market Expansion Approval: Approval from the China National Medical Administration for clinical use of certain products broadens market presence and strengthens competitive advantage.
Negative
Revenue Stagnation in Q4: Total revenue for Q4 2024 was $57.5 million, a 1% decrease over Q4 2023, indicating a stagnation in growth despite previous expectations.
Product Revenue Decline: Product revenue decreased by 3% compared to Q4 2023, attributed to a stronger U.S. dollar and a softer instrument market in the U.S. and EMEA.
U.S. Revenue Decline: Total U.S. revenue declined by 10% compared to Q4 2023, driven by lower instrument sales and foreign exchange effects in EMEA.
Operational Loss Improvement: The company experienced a loss from operations of $20.5 million for the full year 2024, which is a slight improvement but still indicates ongoing financial challenges.
Net Loss Increase: GAAP net loss for the year was $6 million, which increased from a net loss of $12.1 million in the prior year, primarily due to higher foreign exchange losses and lower tax benefits.
Instrument Revenue Challenges: The company anticipates headwinds for instrument revenues in 2025 due to NIH funding cuts, new export controls, and tariffs on imports, which may impact future sales.
Market Challenges Ahead: Despite a strong balance sheet, the company is facing softer market conditions in the U.S. and EMEA, which could hinder growth prospects.
CTKB FAQs
How does CTKB typically perform around its earnings report dates?
Is Cytek Biosciences Inc (CTKB) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CTKB Earning Call Sentiment
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call Transcript
CTKB.O
1.57%Positive
The earnings call summary presents a mixed picture: strong service revenue growth and improved income from operations contrast with declining product revenue and U.S. dollar impact. The Q&A section highlights concerns over tariffs, NIH funding, and unclear management responses, which add uncertainty. Despite a positive share repurchase program and improved EBITDA, the lack of clear guidance and economic headwinds in key markets balance out the positives, leading to a neutral sentiment rating.
